Cefotaxime: Dosing, Indications, Contraindications, and Monitoring
Primary Indications
Cefotaxime is a third-generation cephalosporin indicated for serious bacterial infections including meningitis, sepsis, pneumonia, urinary tract infections, and intra-abdominal infections. The drug demonstrates excellent activity against Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, and Enterobacteriaceae 1.
Key Clinical Uses:
- Bacterial meningitis (meningococcal, pneumococcal, H. influenzae)
- Sepsis and bacteremia
- Complicated urinary tract infections
- Intra-abdominal infections
- Skin and soft tissue infections (necrotizing infections when combined with other agents)
- Gonococcal infections
Dosing Recommendations
Adults
For meningitis in adults, administer cefotaxime 2 g IV every 6 hours 2. This is the preferred empirical regimen for adults under 60 years with suspected bacterial meningitis.
Adult Dosing by Indication 1:
- Uncomplicated infections: 1 g every 12 hours IM or IV
- Moderate to severe infections: 1-2 g every 8 hours IM or IV
- Septicemia: 2 g every 6-8 hours IV
- Life-threatening infections: 2 g every 4 hours IV (maximum 12 g/day)
- Gonococcal urethritis/cervicitis: 0.5 g IM single dose
- Meningococcal meningitis: 2 g every 6 hours IV for 5 days 2
- Pneumococcal meningitis: 2 g every 6 hours IV for 10-14 days 2
For adults ≥60 years with suspected meningitis, add ampicillin 2 g every 4 hours IV to cover Listeria monocytogenes 2.
Pediatric Dosing
For febrile infants 8-21 days old with suspected bacterial infection, use ampicillin PLUS ceftazidime or gentamicin, NOT cefotaxime alone 3. For infants 22-60 days, ceftriaxone is preferred over cefotaxime.
Pediatric Dosing by Age 1:
Neonates (0-1 month):
- 0-1 week: 50 mg/kg/dose IV every 12 hours
- 1-4 weeks: 50 mg/kg/dose IV every 8 hours
Infants and Children (1 month-12 years):
- Standard infections: 50-180 mg/kg/day IV divided every 6-8 hours
- Meningitis: Use higher end of dosing (150-180 mg/kg/day) 1
- Maximum: 12 g/day
Children ≥50 kg: Use adult dosing 1
Specific Pediatric Indications 3:
- UTI (8-21 days): Ampicillin 150 mg/kg/day divided every 8h + ceftazidime 150 mg/kg/day divided every 8h
- Bacterial meningitis (8-28 days): Ampicillin 300 mg/kg/day divided every 6h + ceftazidime 150 mg/kg/day divided every 8h
- Meningitis (29-60 days): Ceftriaxone preferred; if cefotaxime used, 150 mg/kg/day divided every 8h
Renal Impairment Dosing
Cefotaxime is substantially renally excreted; dose adjustment is required in renal impairment 1.
- Monitor renal function in elderly patients and those with known renal disease
- Reduce dose by 40-52% in moderate renal impairment 4
- Reduce dose by 48-52% in severe renal impairment 4
- Avoid doses >6 g/day in patients receiving probenecid 1
The estimated glomerular filtration rate (eGFR) accounts for nearly 50% of plasma level variance 5. Patients with augmented renal clearance may require higher doses to maintain therapeutic levels 6.
Route of Administration
Administer IV for serious infections including meningitis, sepsis, and severe pneumonia 2, 1. IM administration is acceptable for uncomplicated infections and gonorrhea.
IV Administration Considerations:
- Loading dose: 2 g IV for meningitis 5
- Continuous infusion: 6 g/day after 2 g loading dose achieves bactericidal levels in critically ill patients 5
- Monitor infusion sites regularly; change sites if perivascular extravasation occurs 1
- Tissue damage from extravasation may require surgical intervention in rare cases 1
Treatment Duration
Duration varies by infection type and clinical response 2, 1:
- Meningococcal meningitis: 5 days if recovered 2
- Pneumococcal meningitis: 10 days if stable; 14 days if slow response or resistant organism 2
- Group A streptococcal infections: Minimum 10 days 1
- General guideline: Continue 48-72 hours after defervescence or bacterial eradication 1
Contraindications and Precautions
Absolute Contraindications:
- Hypersensitivity to cefotaxime or other cephalosporins
- History of anaphylaxis to beta-lactam antibiotics
Critical Warnings:
Do NOT use cefotaxime in hyperbilirubinemic neonates - ceftriaxone is specifically contraindicated, and while not explicitly stated for cefotaxime, exercise extreme caution 7.
Clostridium difficile-associated diarrhea (CDAD): Can occur up to 2 months after treatment 1. Instruct patients to report watery/bloody diarrhea immediately.
Special Populations:
Pregnancy: Category B - use only if clearly needed 1. Crosses placental barrier; pups in animal studies showed reduced birth weight at high doses.
Nursing mothers: Excreted in breast milk in low concentrations; use with caution 1.
Elderly: Higher risk of toxic reactions due to decreased renal function; monitor renal function and adjust dose 1.
Drug Interactions
Probenecid decreases cefotaxime clearance by ~50% 1. Avoid cefotaxime doses >6 g/day when co-administered with probenecid.
Nephrotoxic drugs (aminoglycosides, NSAIDs, furosemide): May potentiate nephrotoxicity 1.
Tazobactam: Minimal interaction; Cmax increases by only 5.6% 8.
Monitoring Parameters
Essential Monitoring:
Renal function: Baseline and periodic monitoring, especially in elderly and those with known renal disease 1
Hepatic function: New severe hepatobiliary disorders reported in neonates, children, and underweight elderly even with adjusted doses <1 g 9. Monitor liver function tests closely in these populations.
Clinical response:
- Temperature normalization
- Resolution of signs/symptoms
- Bacterial eradication (culture-based when appropriate)
IV site assessment: Regular monitoring for extravasation, infiltration, infection 1
Complete blood count: Cephalosporins can induce positive direct Coombs' test 1
Therapeutic Drug Monitoring:
Target plasma concentrations 5, 6:
- Minimum: >4× MIC for pathogen (e.g., >8 mg/L for Enterobacteriaceae with MIC 2 mg/L)
- Optimal: Maintain concentrations above MIC for 60-70% of dosing interval
- Continuous infusion of 6 g/day after 2 g loading achieves bactericidal levels in critically ill patients 5
Target attainment concerns: Current pediatric dosing may be inadequate for S. pneumoniae, Enterobacteriaceae, and S. aureus in severe sepsis 6. Consider higher doses (150-180 mg/kg/day) for serious infections.
Common Pitfalls
Underdosing in augmented renal clearance: Critically ill children and young adults may have increased clearance requiring higher doses 6
Inadequate coverage in severe sepsis: Standard pediatric dosing achieves adequate levels for N. meningitidis but may fail for S. pneumoniae and other pathogens 6
Forgetting Listeria coverage: Always add ampicillin for patients ≥60 years with suspected meningitis 2
Inappropriate neonatal regimens: Use ampicillin + ceftazidime (or gentamicin) for infants <22 days, NOT cefotaxime alone 3
Ignoring hepatobiliary toxicity: New safety signal in vulnerable populations (neonates, children, underweight elderly) requires intensified liver monitoring 9
Laboratory interference: False-positive urine glucose with copper reduction tests (use enzyme-based tests instead) 1